Terms: = Prostate cancer AND ENO2, HEL-S-279, NSE AND Prognosis
33 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. The Combination of CA125 and nse Is Useful for Predicting Liver Metastasis of Lung cancer.
Wang CF; Peng SJ; Liu RQ; Yu YJ; Ge QM; Liang RB; Li QY; Li B; Shao Y
Dis Markers; 2020; 2020():8850873. PubMed ID: 33376560
[TBL] [Abstract] [Full Text] [Related]
3. The Correlation between PSCA Expression and Neuroendocrine Differentiation in prostate cancer.
Xiang Q; Zhu Z; Luo L; Wang J; Liu Y; Deng Y; Zhou M; Zhao Z
Biomed Res Int; 2020; 2020():5395312. PubMed ID: 33029516
[TBL] [Abstract] [Full Text] [Related]
4. Androgen Deprivation Induces Reprogramming of prostate cancer Cells to Stem-Like Cells.
Sánchez BG; Bort A; Vara-Ciruelos D; Díaz-Laviada I
Cells; 2020 Jun; 9(6):. PubMed ID: 32531951
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract] [Full Text] [Related]
6. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant prostate cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract] [Full Text] [Related]
7. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
Muoio B; Pascale M; Roggero E
Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
[TBL] [Abstract] [Full Text] [Related]
8. Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Cho MH; Kim SH; Park WS; Joung JY; Seo HK; Chung J; Lee KH
World J Surg Oncol; 2016 Oct; 14(1):270. PubMed ID: 27765044
[TBL] [Abstract] [Full Text] [Related]
9. [SMALL CELL CARCINOMA OF THE prostate: A CASE REPORT OF RELATIVE LONG-TERM SURVIVAL].
Hirai M; Konishi T; Saito K; Washino S; Kobayashi Y; Nokubi M; Miyagawa T
Nihon Hinyokika Gakkai Zasshi; 2015 Oct; 106(4):280-4. PubMed ID: 26717788
[TBL] [Abstract] [Full Text] [Related]
10. Clinical management of small-cell carcinoma of the urinary tract: a 10-year single-center's experience.
Carranza OE; Castañón E; Abella LE; Zudaire ME; Castillo A; Arévalo E; Fusco JP; Zudaire JJ; Carías R; Cambeiro M; Martínez-Monge R; Gil-Bazo I
Clin Genitourin Cancer; 2013 Jun; 11(2):168-74. PubMed ID: 23146567
[TBL] [Abstract] [Full Text] [Related]
11. [Paraganglioma of the prostate: a case report and review of the literature].
Chen J; Quan CY; Jiang N; Niu YJ
Zhonghua Nan Ke Xue; 2012 Aug; 18(8):715-8. PubMed ID: 22934517
[TBL] [Abstract] [Full Text] [Related]
12. Focal neuroendocrine differentiation in prostatic gland carcinoma with basaloid pattern.
Gligorijević JV; Velicković LV; Jancić SA; Radovanović Z; Krstić MS; Katić VV
Vojnosanit Pregl; 2011 Jun; 68(6):515-8. PubMed ID: 21818920
[TBL] [Abstract] [Full Text] [Related]
13. [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
Pejcić I; Vrbić S; Filipović S; Sćekić M; Petković I; Pejcić L; Djenić N
Vojnosanit Pregl; 2010 Sep; 67(9):723-31. PubMed ID: 20954411
[TBL] [Abstract] [Full Text] [Related]
14. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells.
Uysal-Onganer P; Kawano Y; Caro M; Walker MM; Diez S; Darrington RS; Waxman J; Kypta RM
Mol Cancer; 2010 Mar; 9():55. PubMed ID: 20219091
[TBL] [Abstract] [Full Text] [Related]
15. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract] [Full Text] [Related]
16. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
Lee SO; Chun JY; Nadiminty N; Lou W; Gao AC
Prostate; 2007 May; 67(7):764-73. PubMed ID: 17373716
[TBL] [Abstract] [Full Text] [Related]
17. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract] [Full Text] [Related]
18. [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan].
Kageyama S; Narita M; Kim CJ; Hanada E; Sakano Y; Iwaki H; Yoshiki T; Okada Y
Hinyokika Kiyo; 2006 Oct; 52(10):809-15. PubMed ID: 17131874
[TBL] [Abstract] [Full Text] [Related]
19. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract] [Full Text] [Related]
20. [Small cell prostatic carcinoma detected at the stage of metastases].
Rabii R; Meziane A; Taha A; Joual A; El Mrini M
Prog Urol; 2004 Sep; 14(4):551-3. PubMed ID: 15776911
[TBL] [Abstract] [Full Text] [Related]
[Next]
